New NICE guideline [NG99] Brain tumours (primary) and brain metastases in adults

New NICE guideline [NG99] Brain tumours (primary) and brain metastases in adults


Published date: July 2018    


This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.


For full guidance
https://www.nice.org.uk/guidance/ng99           

New NIHR Signal Fewer side-effects and similar benefits from shorter chemotherapy after bowel cancer surgery

New NIHR Signal Fewer side-effects and similar benefits from shorter chemotherapy after bowel cancer surgery
Published on 12 June 2018


A three-month course of chemotherapy after surgery for bowel cancer seems no less effective than the standard six-month course, and half as many people suffered from nerve damage as a side-effect. Three-quarters of people survived to three years without disease progression on either treatment.
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-000603/fewer-side-effects-and-similar-benefits-from-shorter-chemotherapy-after-bowel-cancer-surgery

New Technology appraisal guidance [TA526] Arsenic trioxide for treating acute promyelocytic leukaemia

New Technology appraisal guidance [TA526] Arsenic trioxide for treating acute promyelocytic leukaemia
Published date: 13 June 2018  Next review: June 2021


Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.
For full guidance https://www.nice.org.uk/guidance/ta526

New Technology appraisal guidance [TA525] Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Published date: 13 June 2018  Next review: June 2021


Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
For full guidance https://www.nice.org.uk/guidance/ta525

New Technology appraisal guidance [TA524] Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

New Technology appraisal guidance [TA524] Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Published date: 13 June 2018  Next review: June 2021


Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
For full guidance https://www.nice.org.uk/guidance/ta524

New Technology appraisal guidance [TA523] Midostaurin for untreated acute myeloid leukaemia

New Technology appraisal guidance [TA523] Midostaurin for untreated acute myeloid leukaemia
Published date: 13 June 2018                 Next review: June 2021


Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
For full guidance https://www.nice.org.uk/guidance/ta523

New Technology appraisal guidance [TA522] Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

New Technology appraisal guidance [TA522] Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Published date: 13 June 2018                 Next review: More evidence on pembrolizumab is being collected, until November 2019. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then, as part of the managed access agreement


Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial carcinoma in adults.
for full guidance https://www.nice.org.uk/guidance/ta522

New Technology appraisal guidance [TA520] Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy

New Technology appraisal guidance [TA520] Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Published date: 16 May 2018  Next review: May 2021


Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
For full guidance https://www.nice.org.uk/guidance/ta520

New Interventional procedures guidance [IPG615] Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

New Interventional procedures guidance [IPG615] Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy
Published date: May 2018  Next review: this guidance will be reviewed if there is new evidence or safety concerns.




Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.
For full guidance https://www.nice.org.uk/guidance/ipg615

New Interventional procedures guidance [IPG614] Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer

New Interventional procedures guidance [IPG614] Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer
Published date: May 2018  Next review: May 2021


Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer in adults. This involves using heat energy both to clear blockage in the bile ducts before inserting stents and to clear blocked stents.


For full guidance https://www.nice.org.uk/guidance/ipg614

New NICE Technology appraisal guidance [TA519] Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

New NICE Technology appraisal guidance [TA519] Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy


Published date: 25 April 2018  


Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated locally advanced or metastatic urothelial carcinoma in adults.


For full guidance https://www.nice.org.uk/guidance/ta519

New NICE Diagnostics guidance DG32 Adjunctive colposcopy technologies for assessing suspected cervical abnormalities

NICE Diagnostics guidance [DG32] Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I.
Published date: April 2018. Next review: April 2021                


This guidance replaces the NICE diagnostics guidance on adjunctive colposcopy technologies for examination of the uterine cervix – DySIS and the Niris Imaging System (DG4) and the NICE medtech innovation briefing on ZedScan as an adjunct to colposcopy in women with suspected cervical intra‑epithelial neoplasia (MIB20).


Read full guidance at: https://www.nice.org.uk/guidance/dg32

Pembrolizumab for Advanced Hepatocellular Carcinoma – second line onwards

Hepatocellular Carcinoma (HCC) is the most common type of liver cancer. This type of cancer develops from the main liver cells, called hepatocytes. Treatment and survival depends on the stage at which the cancer is diagnosed. HCC is more common in people who have long‐term damage to the liver (cirrhosis) due to a viral infection or excessive alcohol intake.


http://www.io.nihr.ac.uk/report/pembrolizumab-for-advanced-hepatocellular-carcinoma-second-line-onwards/


From the NIHR Innovation Centre

Axitinib for Patients at High Risk of Recurrence of Renal Cell Carcinoma – Adjuvant

Renal cell carcinoma (RCC) is the most common type of kidney cancer. RCC affects the lining of tiny tubes within the kidney which filter waste from the blood, making urine. Symptoms include blood in urine, feeling of lump or mass in the kidney area, weight loss, raised temperature and sweating, back pain on one side (below the ribs), tiredness, loss of appetite and a general feeling of poor health. The main treatment for RCC is surgery to remove the cancer by partly or totally removing the kidney


http://www.io.nihr.ac.uk/report/axitinib-for-patients-at-high-risk-of-recurrence-of-renal-cell-carcinoma-adjuvant/


From the NIHR Innovation Centre

Avelumab for treating metastatic Merkel cell carcinoma [TA 517]

New:  Technology appraisal guidance


Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma in adults.


https://www.nice.org.uk/guidance/ta517

NIHR Signal Common osteoporosis drugs may prevent breast cancer spreading to bone

NIHR Signal Common osteoporosis drugs may prevent breast cancer spreading to bone
          
Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may be small, for example preventing spread to bone or death in about one extra woman in every 100 treated for about five years. This is a complex area because many of the treatments for breast cancer are known to worsen bone thinning, but there are other bone strengthening benefits to these drugs.
Published on 13 March 2018
Read full document at https://discover.dc.nihr.ac.uk/portal/article/4000967/common-osteoporosis-drugs-may-prevent-breast-cancer-spreading-to-bone

NEW NICE Technology appraisal guidance TA513: Obinutuzumab for untreated advanced follicular lymphoma

Obinutuzumab for untreated advanced follicular lymphoma.


Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.


Published: March 2018
Next review: March 2021


Full guidance available at: https://www.nice.org.uk/guidance/ta513

New NICE Technology appraisal guidance TA512: Tivozanib for treating advanced renal cell carcinoma.

Tivozanib for treating advanced renal cell carcinoma.


Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.


Published: March 2018
Next review: March 2021


Full guidance available at https://www.nice.org.uk/guidance/ta512

New NICE Technology appraisal guidance TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma.

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma.

Evidence-based recommendations on daratumumab (Darzalex) for relapsed or refractory multiple myeloma in adults.

Published March 2018
Next review: The guidance will be updated when the data collection period has ended (expected to be November 2020). Daratumumab will continue to be available through the Cancer Drugs Fund while the guidance is being updated, as part of the managed access agreement.


Full guidance available at https://www.nice.org.uk/guidance/ta510

NICE Guidance Technology appraisal guidance TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer.

Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2‑positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER‑2 therapy before, in adults.

Published March 2018
Next review: September 2022


Full guidance available at https://www.nice.org.uk/guidance/ta509